Pharmacokinetics and brain sigma 1 (σ1) receptor occupancy of MR309, a selective σ1 receptor antagonist
Eugenii A. Rabiner,1a Kevin Smith,2a,b Carla Bennett,2 Gaia Rizzo1, Yvonne Lewis1
Gill Mundin,2b Helen Dooner,2bAlexander Oksche2b,3,4
1. Invicro(former Imanova Ltd), A Konica Minolta Company, London, UK
2. Mundipharma Research Limited, Cambridge, UK
3. Institut für medizinische und pharmazeutische Prüfungsfragen, Mainz, Germany
4. Rudolf-Buchheim Institute of Pharmacology, Giessen, Germany
aER and KS are co-lead authors
bAffiliation reflects the period when the study was conducted (AO, HD, GM and KS are no longer employees of Mundipharma Research Limited).